Cardio Diagnostics Holdings (CDIO) Income from Continuing Operations (2021 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Income from Continuing Operations of 1788158.0 for Q1 2026, down 22.03% sequentially from 1465368.0 in Q4 2025, and down 9.36% YoY from 1972882.56 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Income from Continuing Operations for 6 years, with the latest figure at 1788158.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 9.36% year-over-year to 1788158.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6651261.0 (down 13.6% YoY) and the FY2025 annual result came in at 5133552.0, up 38.77% from the prior year.
- Income from Continuing Operations declined to 1788158.0 in Q1 2026 per CDIO's latest filing, from 1465368.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 290055.0 in Q1 2022 and troughed at 4163584.0 in Q1 2024.
- A 5-year average of 1747505.71 and a median of 1519308.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations plunged 211990.18% in 2022, then jumped 67.98% in 2024.
- Over 5 years, Income from Continuing Operations stood at 2378057.0 in 2022, then surged by 41.59% to 1388929.0 in 2023, then fell by 9.39% to 1519308.0 in 2024, then rose by 3.55% to 1465368.0 in 2025, then slipped by 22.03% to 1788158.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 1788158.0, 1465368.0, and 1714536.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Cardio Diagnostics Holdings | 6.42 Mn | 835,350.96 | - | -1.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.50 Mn |
| Mar 31, 2026 | -1.79 Mn |
| Dec 31, 2025 | -1.47 Mn |
| Sep 30, 2025 | -1.71 Mn |
| Jun 30, 2025 | -1.68 Mn |
| Mar 31, 2025 | -1.64 Mn |
| Dec 31, 2024 | -1.52 Mn |
| Sep 30, 2024 | -1.41 Mn |
| Jun 30, 2024 | -1.29 Mn |
| Mar 31, 2024 | -4.16 Mn |
| Dec 31, 2023 | -1.39 Mn |
| Sep 30, 2023 | -1.93 Mn |
| Jun 30, 2023 | -4.02 Mn |
| Mar 31, 2023 | -1.03 Mn |
| Dec 31, 2022 | -2.38 Mn |
| Sep 30, 2022 | -1.15 Mn |
| Jun 30, 2022 | -841,998.00 |
| Mar 31, 2022 | -290,055.00 |
| Dec 31, 2021 | -144,837.00 |
| Sep 30, 2021 | -721.00 |